←
Nicole Chambers, PhD583 posts
Nicole Chambers, PhD avatar

Nicole Chambers, PhD

@Nicholinergic

K99/R00 Postdoc @UF @LabMoehle @UF_Pharmacology Neuroscience, Movement Disorders, Electrophysiology PhD @binghamtonuniv2 Loves frogs, painting, kayaking

◷ Joined June 2010▧ 89 Photos and videos
Nicole Chambers, PhD avatar
Nicole Chambers, PhD@Nicholinergic·28 Aug 2024

I’m thrilled to share one of my postdoctoral projects in @LabMoehle ! We created a new mouse model of GNAL-linked dystonia which shows overt dystonia-like symptoms and hyperexcitability in striatal SPNs. Thank you to everyone who contributed to this work! biorxiv.org/content/10.1101/…

Nicole Chambers, PhD avatar
Nicole Chambers, PhD@Nicholinergic·Mar 26

In addition to investigating M5 receptor modulation, this study is the first to characterize Erasmus Ladder deficits in the 6-OHDA lesioned mouse. 6/n

Nicole Chambers, PhD avatar
Nicole Chambers, PhD@Nicholinergic·Mar 26

Importantly, M5 positive allosteric modulation did not cause robust dyskinesia of its own, nor did it worsen L-DOPA-induced dyskinesia. Overall this suggests targeted M5 receptors modulation as a novel therapeutic target for PD. 5/n

Nicole Chambers, PhD avatar
Nicole Chambers, PhD@Nicholinergic·Mar 26

Overall we found that positive allosteric modulation of M5 receptors reduced bradykinesia and decreased percentage of short steps in the Erasmus ladder. These improvements were positively correlated with the percentage of remaining TH+ neurons 3/n

Nicole Chambers, PhD avatar
Nicole Chambers, PhD@Nicholinergic·Mar 26

M5 receptors are located on cell bodies of SNc and VTA dopamine neurons as well as nigrostriatal dopamine terminals. Therefore positive allosteric modulation of Gq-coupled M5 receptors may be a promising therapeutic target for PD. 2/n

Nicole Chambers, PhD avatar
Nicole Chambers, PhD@Nicholinergic·Mar 26

Excited to share my recent first author publication from my postdoc in @LabMoehle ! ⬇️⬇️⬇️ We investigated postive allosteric modulation of M5 muscarinic acetylcholine receptor in the 6-OHDA lesioned mouse model 1/n tinyurl.com/vrfhttm5

UF_Pharmacology avatar
⟳ Nicole Chambers, PhD retweeted
UF_Pharmacology@UF_Pharmacology·Feb 5

We are pleased to announce Dr. Mark Moehle, Ph.D., has been awarded ASPET's 2026 Division for Neuropharmacology Early Career Award! 🎉 Please join us in congratulating Dr. Moehle for this achievement!

Post attachment
UF McKnight Brain Institute avatar
⟳ Nicole Chambers, PhD retweeted
UF McKnight Brain Institute@UFMBI·14 Jul 2025

180+ neuroscientists & trainees from across US & abroad discussed latest research in Alzheimer’s, Parkinson’s, ALS, dementia @UF-hosted International Research Conference on Neurodegenerative Diseases July 9-12, co-sponsored by the MBI. Learn more: bit.ly/3IqGzzq

Post attachmentPost attachmentPost attachmentPost attachment
Nicole Chambers, PhD avatar
Nicole Chambers, PhD@Nicholinergic·25 Feb 2025

Congrats, Mark!! Well deserved! I’m excited to be among those in @LabMoehle who are presenting research at @UFMedicine Celebration of Research tonight from 5-7.

Incredibly honored to be awarded the Rising Star Award by @UFMedicine and @UFMedResearch. This would not be possible without all the wonderful people who work in the lab and the incredible environment at @UF_Pharmacology and @UFCTRND

Alexandra Nelson avatar
⟳ Nicole Chambers, PhD retweeted
Alexandra Nelson@NelsonLabUCSF·14 Oct 2024

In this new preprint, Emily Twedell (PhD student) and colleagues identify a functional role for the inhibitory synapses between striatal projection neurons -- shaping striatal ensembles to promote healthy action selection. biorxiv.org/content/10.1101/…

Nicole Chambers, PhD avatar
Nicole Chambers, PhD@Nicholinergic·9 Oct 2024

If you’re still here at @SfNtweets, come and see posters from @LabMoehle ! This morning Iggy presents electrophysiological and cognitive changes in the PFF model of PD and this afternoon I will present electrophysiology and behavioral data from our Gnal linked dystonia mouse.

Post attachment